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Background: Cellular FLICE-Inhibitory Protein (long form, c-FLIPL) is a critical negative regulator of death
receptor-mediated apoptosis. Overexpression of c-FLIPL has been reported in many cancer cell lines and is
associated with chemoresistance. In contrast, down-regulation of c-FLIP may drive cancer cells into cellular
apoptosis. This study aims to demonstrate that inhibition of the heat shock protein 90 (Hsp90) either by inhibitors
geldanamycin/17-N-Allylamino-17-demethoxygeldanamycin (GA/17-AAG) or siRNA technique in human lung cancer
cells induces c-FLIPL degradation and cellular apoptosis through C-terminus of Hsp70-interacting protein
(CHIP)-mediated mechanisms.
Methods: Calu-1 and H157 cell lines (including H157-c-FLIPL overexpressing c-FLIPL and control cell H157-lacZ)
were treated with 17-AAG and the cell lysates were prepared to detect the given proteins by Western Blot and the
cell survival was assayed by SRB assay. CHIP and Hsp90 α/β proteins were knocked down by siRNA technique. CHIP
and c-FLIPL plasmids were transfected into cells and immunoprecipitation experiments were performed to testify
the interactions between c-FLIPL, CHIP and Hsp90.
Results: c-FLIPL down-regulation induced by 17-AAG can be reversed with the proteasome inhibitor MG132, which
suggested that c-FLIPL degradation is mediated by a ubiquitin-proteasome system. Inhibition of Hsp90α/β reduced
c-FLIPL level, whereas knocking down CHIP expression with siRNA technique inhibited c-FLIPL degradation.
Furthermore, c-FLIPL and CHIP were co-precipitated in the IP complexes. In addition, overexpression of c-FLIPL can
rescue cancer cells from apoptosis. When 17-AAG was combined with an anti-cancer agent celecoxib(CCB), c-FLIPL
level declined further and there was a higher degree of caspase activation.
Conclusion: We have elucidated c-FLIPL degradation contributes to apoptosis induced by Hsp90 inhibition,
suggesting c-FLIP and Hsp90 may be the promising combined targets in human lung cancer treatment.
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Caspase-8 activation plays an important role in the
death receptor-mediated extrinsic apoptotic pathway in
human cancer cells [1]. When binding to ligands, the
death receptor is activated and forms the death induced
signal complex (DISC) together with FADD and procas-
pase-8. Procaspase-8 is activated and initiates the cas-
pase cascade which mediates cellular apoptosis. c-FLIPL
is a major protein that can prevent caspase-8/10 activa-
tion in the DISC and inhibiting apoptosis mediated by
death receptors. It has been found that c-FLIPL is up-
regulated in several carcinomas [2,3] and overexpression
of c-FLIPL can be responsible for chemoresistance and
malignant transformation [4-6]. To date, more than 10
splicing variants of c-FLIP genes have been identified at
the mRNA level. However, only c-FLIPL and c-FLIPS
have been extensively studied at the protein level.
Although these two splicing variants have distinct struc-
tural and functional properties, they have been found to
be recruited to DISC and to inhibit caspase-8 activation.
Recent studies have shown that c-FLIPL degradation is
dependent on JNK-mediated E3-ligase Itch and AKT
phosphorylation, while degradation of c-FLIPS seems to
have different pattern [7,8].
Hsp90 is a pleiotropic molecular chaperone and functions
as a key protein in the conformational maturation and
stability of client proteins, many of which are kinases, cell
cycle regulators and steroid receptors, etc. [9]. These client
proteins play important roles in signaling transduction, cell
proliferation and cancer chemoresistance. The Hsp90-
based molecular chaperone complex interacts with its client
proteins in an iterative way. Hsp90 cycles are driven by
ATP- or ADP-bound conformations that are mediated via
multiple rounds of ATP binding and hydrolysis [9]. Hsp90
inhibitors such as geldanamycin (GA) or its synthetic
analogue 17-AAG, directly binds to the ATP-binding
pocket in the N-terminal domain of Hsp90 and, hence,
blocks the binding of nucleotides to Hsp90. Once Hsp90
activity is inhibited, the Hsp90-dependent protein dissoci-
ates from the multi-chaperone complexes and is targeted
for degradation by the ubiquitin-proteasome system
[10,11]. 17-AAG-induced apoptosis has been previously
reported to be associated with c-FLIPS down-regulation
[12]. However, the relationship between Hsp90 and c-FLIPL
has not been well elucidated.
C-terminus of Hsp70-interacting protein (CHIP) has the
E3 ligase activity, and it binds to Hsp/Hsc70 and Hsp90
complex by means of its TPR (an amino-terminal tetratri-
copeptide) domain [13]. It has been reported that CHIP
degrades Hsp90 client proteins, such as the glucocorticoid
receptor, the cystic fibrosis transmembrane-conductance
regulator and ErbB2 [13-15]. In this study, we show that
CHIP is involved in c-FLIPL degradation induced by Hsp90
inhibition. Since both Hsp90 and c-FLIPL play a critical rolein oncogenesis and chemoresistance, inhibition of Hsp90
by 17-AAG in combination with therapeutic agents target-
ing c-FLIP may be an efficacious strategy in patients with
tumors that express high levels of c-FLIPL and other Hsp90
client proteins.Results
Hsp90 inhibitor 17-AAG and GA induces c-FLIPL down-
regulation via ubiquitin-proteasome pathway in NSCLC
cells
17-AAG-induced apoptosis has been previously reported to
be associated with c-FLIPS down-regulation [12]. However
the relationship between 17-AAG/GA and c-FLIPL has not
been well elucidated. In this study we examined the effect
of c-FLIPL expression induced by 17-AAG or GA in lung
cancer cell lines including Calu-1, A549, H460 and H157.
After treatment with 17-AAG and GA at the indica-
ted concentrations for 48 h, c-FLIPL levels were reduced
(Figure 1A and B). We also performed time course expe-
riments to monitor the expression of c-FLIPL. Calu-1
and H157 cells were treated with 17-AAG (1.0 μM) or
GA(4.0 μM) for the indicated time. We found that the
c-FLIPL expression decreased in a time-dependent man-
ner. In Calu-1 and H157 cells, the time of c-FLIPL down-
regulation occurred as early as 4 h and was sustained for at
least 48 h following 17-AAG or GA exposure (Figure 1C).
It has been reported that c-FLIPL degradation is corre-
lated with ubiquitin [7]. To determine whether 17-AAG
induces proteasome-mediated c-FLIPL degradation, we
tested the effects of 17-AAG and GA on c-FLIPL expres-
sion in the absence or presence of the proteasome inhibi-
tor MG132 in Calu-1 and H157 cells. As shown in
Figure 2A and B, MG132 at the concentration of 20 μM
abrogated the ability of 17-AAG and GA to reduce
c-FLIPL, suggesting that 17-AAG- and GA-induced
c-FLIPL down-regulation is dependent on proteasome-
mediated degradation pathway.Inhibition of Hsp90 expression induces c-FLIPL down-
regulation
It has been documented that 17-AAG and GA
induced degradation of Hsp90 client proteins [9].
Since we detected that c-FLIPL down-regulation was
induced by 17-AAG and GA, we wondered whe-
ther c-FLIPL was a client protein of Hsp90. We
knocked down Hsp90α/β with siRNA and then de-
tected the c-FLIPL and Hsp90α/β protein levels by
Western blot. Hsp90α/β protein levels were reduced
after knockdown, and the c-FLIPL level was also de-
creased compared to the control (Figure 3A and B),
suggesting Hsp90 controls the stability of c-FLIPL
protein.
Figure 1 17-AAG and GA induces c-FLIPL down-regulation in NSCLC cells. (A) and (B), Calu-1, H157, A549 and H460 cell lines were treated
with either 17-AAG or GA at the indicated concentration for 48 h. (C), Calu-1 and H157 cells were treated with 1.0 μM 17-AAG or 4.0 μM GA for
the indicated time. The cells were subjected to preparation of whole-cell protein lysates and c-FLIPL proteins were detected by Western blot
analysis.
Figure 2 17-AAG and GA induce c-FLIPL down-regulation via proteasome pathway. Calu-1 and H157 cells were pretreated with 20 μM
MG132 for 30 min and co-treated with the indicated concentrations of 17-AAG (A) or GA (B) for 4 h, and then the cells were subjected to
preparation of whole-cell protein lysates and c-FLIPL proteins were detected by Western blot analysis.
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Figure 3 Inhibition of Hsp90 expression facilitates c-FLIPL down-regulation. (A) and (B), Calu-1 and H157 cells were transfected with siRNAs
of control, Hsp90α and Hap90β, respectively. Twenty four hours later, cells were treated with 1.0 μM 17-AAG for 48 h. The cells were harvested for
Western blot analysis to detect Hsp90α/β and c-FLIPL levels.
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CHIP interacts with Hsp90 chaperone complexes and
displays E3-ligase activity to degrade Hsp90 client
proteins [13,15]. In order to detect the interaction of
CHIP with c-FLIPL, we explored dose experiments in
Calu-1 and H157 cells. We found that c-FLIPL level was
reduced while CHIP expression was slightly increased
after treatment with 17-AAG (Figure 4A and B). Fur-
thermore, when CHIP was knocked down, the degrada-
tion of c-FLIPL was abrogated (Figure 4C) in Calu-1 and
H157 cells, which indicated that c-FLIPL degradation
was modulated by CHIP.
CHIP interacts with c-FLIPL in vivo and promotes the
ubiquitination of c-FLIPL
To further test if there is physically interaction between
CHIP and c-FLIPL, immunoprecipitation experiments were
performed. Calu-1 cells were transfected with plasmids
carrying Myc-tagged CHIP or Flag-tagged c-FLIPL and then
treated with 1.0 μM 17-AAG for 4 h, the lysate supernatant
was incubated with Myc antibody for 1 h and then with
protein-G and protein-A (1:1 mix) beads overnight
(left panel), or anti-FLAG M2 Affinity Gel beads overnight
directly(right panel). Western Blot analysis showed that
CHIP and c-FLIPL proteins were both detected in the
immunoprecipitation complexes, suggesting that bothexogenous and endogenous CHIP interacts with c-FLIPL
physically in vivo. Hsp90 was also pulled down together
with c-FLIPL and CHIP, suggesting that CHIP interacts
with c-FLIPL in an Hsp90 chaperone complex (Figure 4D).
Considering CHIP can be an E3 ligase, we wonder if it can
regulate the ubiquitination level of c-FLIPL. H157-c-FLIPL
cells were transfected with plasmids carrying Myc-tagged
CHIP or Myc-tagged CHIP (H260Q Mutant) and then
treated with 1.0 μM 17-AAG for 8 h. After immunoprecipi-
taion with Flag antibody, Flag-tagged c-FLIPL was pulled
down. Western Blot analysis showed that CHIP overexpres-
sion promoted the c-FLIPL ubiquitination, while the mutant
CHIP overexpression suppressed the c-FLIPL ubiquitination
after 17-AAG treatment (Figure 4E). Taken together, our
data suggest that CHIP interacts with c-FLIPL in vivo and
promotes the ubiquitination of c-FLIPL.
Ectopic overexpression of c-FLIPL protects cancer cells
from apoptosis
To determine the effect of c-FLIPL overexpression on
17-AAG- and GA-induced apoptosis, two cell clones
H157-c-FLIPL and H157-LacZ that overexpress c-FLIPL
and LacZ respectively were used to examine their effects
on 17-AAG- and GA-induced caspase activation and
apoptosis. By Western blotting, we detected high levels
of ectopic c-FLIPL in the H157-c-FLIPL cell line. We
Figure 4 CHIP is involved in c-FLIPL degradation. (A), Calu-1 and H157 cells were treated with the indicated concentrations of 17-AAG for
48 h. (B), Calu-1 and H157 cells were treated with 1.0 μM 17-AAG for the indicated time. (C), Calu-1 and H157 cells were transfected with control
siRNA (Crtli) and CHIP siRNA (CHIPi). 24 h after transfection, cells were reseeded and treated with 1.0 μM 17-AAG for 48 h. (D), Calu-1 cells were
transfected with pcDNA-Myc-CHIP plasmid, and the cells were treated with 20 μM MG132 and 1.0 μM 17-AAG for 4 h. For immunoprecipitation,
cell lysate was incubated with Myc antibody for 1 h and then incubated with protein A/G agarose(1:1 mix) at 4°C overnight(Left panel). Calu-1
cells were transfected with Lenti-Flag-c-FLIPL, and the cells were treated with 1.0 μM 17-AAG and 20 μM MG132 for 4 h. For immunoprecipitation,
cell lysate was incubated with Anti-FLAG M2 beads at 4°C overnight (Right panel). The precipitated proteins were analyzed by Western Blot assay.
(E), H157/c-FLIPL cells were transfected with plasmids Ub-HA and pcDNA-Myc-CHIP or pcDNA-Myc-CHIP(H260Q mutant), and then the cells were
treated with 1.0 μM 17-AAG and 20 μM MG132 for 8 h. The cell lysates were subjected to immunoprecipitation with Flag antibody and
subsequently Western Blot analysis.
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pase-8, caspase-9, caspase-3 and cleavage of PARP in
H157-LacZ control cells, as demonstrated by increased
levels of cleaved bands (Figure 5A). This was not seen
in the corresponding H157-c-FLIPL cells. We measured
the survival of H157-LacZ to be 32.4% in cells treated
with 2.0 μM 17-AAG for 48 h, whereas the survival of
H157-c-FLIPL cells were more than 58.1% (Figure 5B) by
SRB assay. The similar result was observed for SRB assay
in GA-treated cells. From the above results, we conclude
that ectopic overexpression of c-FLIPL protects cancer
cells from apoptosis induced by Hsp90 inhibition.
17-AAG enhances celecoxib-induced c-FLIPL down-
regulation and apoptosis
We have reported that celecoxib (CCB) down-regulates
c-FLIPL through ubiquitin-proteasome degradation [16].
To determine whether 17-AAG enhances celecoxib-
induced c-FLIPL down-regulation and apoptosis, weinvestigated the level of c-FLIPL expression and caspase
activation by combination treatment with CCB and
17-AAG in Calu-1 cells. We found that 17-AAG combin-
ation with CCB had synergistic effects on apoptosis induc-
tion by Western blotting and SRB assay (Figure 6A and B).
c-FLIPL expression decreased further when 17-AAG was
combined with CCB compared with the monotherapy
Calu-1 cells. In addition, the activation of caspase-8,
caspase-9, caspase-3 and the cleavage of PARP were more
pronounced. This data suggests that 17-AAG may enhance
chemotherapeutic agent-induced c-FLIPL down-regulation
and apoptosis in lung cancer cells.
Discussion
Hsp90 plays a key role in conformational maturation
and stability of client proteins in transducing prolifera-
tive and anti-apoptotic signals [10]. In the present study
we found that Hsp90 inhibitor 17-AAG and GA or
Hsp90 knockdown induced c-FLIPL down-regulation
Figure 5 Stable overexpression of exogenous c-FLIPL protects cells from 17-AAG- or GA-induced caspase activation and growth
inhibition in human NSCLC cell lines. (A), H157 cells stably expressing lacZ (H157-lacZ) and c-FLIPL (H157-c-FLIPL) were treated with the
indicated concentrations of 17-AAG or GA for 48 h and then the cells were subjected to Western blot analysis for detection of caspase activation
and PARP cleavage. (B), H157-lacZ and H157-c-FLIPL cells were cultured in the 96-well plates and then treated with the given concentrations of
17-AAG or GA for 48 h, then the cell number was estimated by SRB assay to determine the cell survival. Differences between groups are
evaluated by Student’s t-test. Columns, mean of triplicate treatments; bars, ± SD. The statistical differences between the two treatments were
analyzed by two-sided unpaired Student’s t tests (*P<0.05; **P<0.01; *** P<0.001).
Figure 6 17-AAG enhances celecoxib-induced c-FLIPL down-regulation and apoptosis. (A), Calu-1 cells were treated with 17-AAG, celecoxib
alone, and their respective combinations. After treatment for 48 h, the cells were subjected to detection of caspase activation and PARP by
Western blot assay. (B), Calu-1 cells were seeded in 96-well plate and on the second day were treated with the given concentrations of CCB or
combined concentrations of 17-AAG and CCB for 48 h, and then the cell number was estimated by SRB assay to determine the cell survival.
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Although DR5 is an important death receptor in the
extrinsic apoptotic pathway, in the above experiments,
we failed to detect DR5 up-regulation (data no shown).
This indicates that c-FLIPL may primarily contribute to
Hsp90 inhibition-induced apoptosis in lung cancer cells.
Currently, more than one hundred client proteins of
Hsp90 have been identified, and they are degraded when
Hsp90 multi-chaperone complex activity is disrupted by
the inhibitors. When we inhibited Hsp90 expression
using siRNA technique and examined the c-FLIPL level,
we found c-FLIPL was reduced in the cells whose Hsp90
was knocked down, suggesting that c-FLIPL is a client
protein of Hsp90. It is reported when Hsp90 is inhibited,
it recruits E3 ligase (e.g. CHIP) to degrade the client
proteins [13-15]. When we knocked down CHIP, c-FLIPL
degradation was inhibited after treatment with 17-AAG,
which indicated that CHIP modulated c-FLIPL degrad-
ation in the NSCLC cell lines. Next, we performed
immunoprecipitation experiments in Calu-1 cell lines.
We found that CHIP was co-precipitated with c-FLIPL
in the precipitated complex. We also found that Hsp90
was precipitated at the same time, hinting that c-FLIPL
is the client protein of Hsp90 and CHIP modulates
c-FLIPL degradation through the Hsp90 chaperone com-
plex. Itch is reported as an E3 ligase of c-FLIPL in the
mouse cells upon exposure to TNFα [7]. However, it has
also been reported that some agents induced c-FLIPL
degradation independently of Itch [17-19]. Additionally,
we found that CHIP promotes the ubiquitination of
c-FLIP, indicating CHIP regulates c-FLIPL degradation
through uibiquitination when the cells were treated with
17-AAG.
It has been investigated that the clinically used anti-
inflammatory drug celecoxib induces c-FLIPL down-
regulation and facilitates cancer cell apoptosis alone or in
combination with other agents [16]. We found that
17-AAG and celecoxib had synergistic effects in promoting
c-FLIPL down-regulation and cellular apoptosis. In addition,
overexpression of c-FLIPL could rescue cancer cells from
apoptosis. These data suggest that c-FLIPL down-regulation
plays important role in Hsp90 inhibition-induced apoptosis
in NSCLC cells.
Conclusions
Our data reveals that c-FLIPL is down-regulated and apop-
tosis is induced effectively by Hsp90 inhibition, either by
17AAG and GA or siRNA technique, and c-FLIPL is
degraded via proteasome-mediated pathway. CHIP modu-
lates c-FLIP degradation induced by Hsp90 inhibition in
human NSCLC cell lines. Targeting both c-FLIPL and
Hsp90 may represent a promising therapeutic strategy for
the patients whose tumors overexpress c-FLIPL and Hsp90
client proteins.Materials and methods
Reagents and antibodies
17-AAG and GA were purchased from LC Laboratories
(Pompano Beach). Celecoxib, MG132 and Anti-FLAG
M2 Affinity Gel were purchased from Sigma (St. Louis,
MO). Protein A and Protein G Agarose were purchased
from Roche (Mannheim, Germany).
Mouse anti-caspase-3 and anti-caspase-8 monoclo-
nal antibodies, rabbit anti-caspase-9 and anti-poly
(ADP-ribose) polymerase (PARP) antibodies were
purchased from Cell Signaling Technology (Danvers,
MA). Mouse anti-FLIPL monoclonal antibody was
purchased from Alexis Biochemicals (San Diego, CA).
Mouse anti-Hsp90 antibodies were purchased from
Abcam (Cambridge, UK). Mouse anti-Myc and anti-
β-actin antibodies, rabbit anti-Flag and anti-CHIP
antibodies were purchased from Sigma (St. Louis,
MO).
Cell lines, cell culture and transfection
The human non-small cell lung cancer cell lines used in
this study were obtained from the American Type Culture
Collection (Manassas, VA) and were grown in RPMI 1640
supplemented with 5% fetal bovine serum at 37°C in a
humidified atmosphere of 5% CO2 and 95% air. Cells were
transfected with different plasmids by using the FuGene
reagent from Roche (Indianapolis, IN), according to the
manufacturer’s instructions.
Cell survival assay
Cells were seeded in 96-well plate with an appropriate
amount in 100 μL culture medium per well. On the
second day, compounds or drugs were mixed in and the
total volume of per well was 200 μL. Cells were treated
for defined time and then cell viability was measured by
sulforhodamine B (SRB) assay as described previously
[20].
Western blot analysis
The whole-cell protein lysates preparation and Western
blot analysis were described in reference [21].
Plasmids and establishment of stable cell lines that
overexpress c-FLIPL
Plasmids of Myc-CHIP and Myc-CHIP (H260Q) were
kindly provided by Dr. Hamid Band (University of
Nebraska Medical Center, USA). Lenti-Flag-c-FLIPL was
constructed before [22]. The cell clones that can overex-
press c-FLIPL and LacZ were constructed as previously
described [22].
Knockdown of Hsp90, CHIP expression with siRNA
siRNAs were synthesized by GenePharma (Shanghai,
China). Control siRNA and Hsp90α/β siRNA target
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of CHIP siRNA was 50-AGGCCAAGCACGACAAGTA-30.
Transfection of siRNA was conducted as previously
described [22].
Immunoprecipitation
To precipitate Flag-tagged FLIPL or Myc-tagged CHIP
proteins, cells were lysed with lysis buffer and Anti-FLAG
M2 Affinity Gel beads or Myc antibody with Protein A/G
Agarose beads (1:1 mix) were used to pull down
Flag-tagged FLIPL or Myc-tagged CHIP proteins according
to the manufacture’s instructions.
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